Evolus (EOLS) Capital Expenditures (2018 - 2026)
Evolus (EOLS) posted Capital Expenditures of $12000.0 for Q1 2026, down 98.25% on a QoQ basis from $687000.0 in Q4 2025, and down 96.24% year-over-year from $319000.0 in Q1 2025.
Evolus (EOLS) Capital Expenditures (2018 - 2026) Analysis & Trends
Evolus' Capital Expenditures history runs 9 years deep, the most recent figure standing at $12000.0 for Q1 2026.
- Quarterly Capital Expenditures fell 96.24% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 206.45% YoY) and the FY2025 annual result came in at $5.0 million, up 240.42% from the prior year.
- Capital Expenditures was $12000.0 for Q1 2026 at Evolus, down from $687000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.8 million in Q2 2025 and bottomed at -$296000.0 in Q3 2024.
- A 5-year average of $545117.6 and a median of $346000.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 13033.33% — and 2024, when it sank 158.04%.
- Evolus' Capital Expenditures stood at $866000.0 in 2022, then tumbled by 82.45% to $152000.0 in 2023, then soared by 188.16% to $438000.0 in 2024, then jumped by 56.85% to $687000.0 in 2025, then sank by 98.25% to $12000.0 in 2026.
- Business Quant data shows EOLS's Capital Expenditures at $12000.0 in Q1 2026, $687000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Sep 30, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Mar 31, 2025 | 319,000.00 |
| Mar 31, 2025 | 319,000.00 |
| Dec 31, 2024 | 438,000.00 |
| Dec 31, 2024 | 438,000.00 |
| Sep 30, 2024 | -296,000.00 |
| Sep 30, 2024 | -296,000.00 |
| Jun 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 256,000.00 |
| Mar 31, 2024 | 256,000.00 |
| Dec 31, 2023 | 152,000.00 |
| Dec 31, 2023 | 152,000.00 |